Occult systemic Non-Hodgkin's Lymphoma (NHL) in patients initially diagnosed as Primary Central Nervous System Lymphoma (PCNSL): How much staging is enough?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To demonstrate the extent of staging necessary to exclude occult systemic stage IV NHL before making a diagnosis of stage I AE PCNSL.
The diagnosis of PCNSL requires the demonstration of malignant lymphocytes within the CNS (usually by biopsy) and finding no evidence of systemic NHL. Different staging approaches have been recommended, ranging from extensive systemic evaluation (including bone marrow examination) to a more focused approach (abdominal and pelvic CT) to no systemic evaluation. We have employed a staging regimen that included: ophthalmologic evaluation (including slit lamp examination); CT of chest, abdomen, and pelvis; bilateral iliac crest aspirate and biopsy; flow cytometry of circulating lymphocytes; and, in men, testicular ultrasound.
We carried out a retrospective review of 128 patients entered into the Mayo Lymphoma Project data bank (1975–1994).
Between the years 1975 and 1994, five patients (3.9%) were identified who fulfilled criteria for the diagnosis of PCNSL (typical clinical history, pathognomonic neuro-imaging, and histologie proof of NHL in brain tissue) but who had occult systemic NHL on staging (bone marrow 1, abdominal lymph nodes 3), or at autopsy (colon 1). Case histories are presented.
Patients with apparent PCNSL may have systemic NHL. Complete staging is essential to the initial management of patients presenting as PCNSL to exclude systemic stage IV disease.
- O'Neill BP, Kelly PJ, Earle JD, Scheithauer B, Banks PM: Computer-assisted stereotaxic biopsy for the diagnosis of primary central nervous system lymphoma. Neurology 37: 1160–1164, 1987
- Feiden W, Bise K, Steude U: Diagnosis of primary cerebral lymphoma with particular reference to CT-guided stereo tactic biopsy. Virchows Arch A 417: 21–28, 1990
- O'Neill BP, Illig JJ: Primary central nervous system lymphoma. Mayo Clin Proc 64: 1005–1020, 1989
- Jellinger KA, Paulus W: Primary central nervous system lymphomas — an update. J Cancer Res Clin Oncol 119: 7–27, 1992
- DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G: Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40: 80–86, 1990
- Glass J, Gruber ML, Cher L, Hochberg GH: Pre-irradiation methotrexate chemotherapy of primary central nervous system lymphomas: long-term outcome. J Neurosurg 81:188–195, 1994
- Cristea R, Benbadis S, Rogers L, Estes M: Yield of systemic staging in patients presenting as parenchymal brain lymphoma. Ann Neurol 36: 294, 1994
- Jack CR, O'Neill BP, Banks PM, Reese DF: Primary central nervous system lymphoma: histologic types and CT appearance. Radiology 167: 211–215, 1988
- Tomlinson FH, Kurtin PJ, Suman VJ, Scheithauer BW, O'Fallon JR, Kelly PJ, Jack CR, O'Neill BP: Primary intracerebral malignant lymphoma: a clinicopathologic study of 89 patients. J Neurosurg (in press)
- Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68: 835–853, 1988
- Peterson K, Gordon KB, Heinemann M-H, DeAngelis LM: The clinical spectrum of ocular lymphoma. Cancer 72: 843–849, 1993
- Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H: Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. Cancer 74: 1383–1397, 1994
- Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomas JW, Murray KJ: Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9–17, 1992
- Murray K, Kun L, Cox J: Primary malignant lymphoma of the central nervous system: results of treatment of 11 cases and review of the literature. J Neurosurg 65: 600–607, 1986
- Ervin T, Canellos GP: Successful treatment of recent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45: 1556–1557, 1980
- Stewart DJ, Russell N, Atack EA, Petti MC, Motta M, Salvagnini M, Meloni G, Martelli M, Monarca B, Mandelli F: Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report. Cancer Treat Rep 67: 287–291, 1983
- Amadori S, Papa G, Avvisati Get al: Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J Clin Oncol 2: 98–101, 1984
- Frick JC, Hanse RM, Anderson T, Ritch PS: Successful high-dose intravenous cytarabine treatment of parenchymal brain involvement from malignant lymphoma. Arch Intern Med 146: 791–792, 1986
- Levitt LJ, Dawson DM, Rosenthal DS, Maloney WC: CNS involvement in the non-Hodgkin's lymphomas. Cancer 45: 545–552
- Shimodaira M, Tsukamoto Y, Niwa Y, Goto H, Hase S, Hayakawa T, Nagasaka T: A proposed staging system for primary gastric lymphoma. Cancer 73: 2709–15, 1994
- Wiseman GA, Witzig TE, Mullan BP: Imaging of Hodgkin's disease and non-Hodgkin's lymphoma with Indium In-111 pentetreotide. J Nucl Med 35: 132P, 1994
- Occult systemic Non-Hodgkin's Lymphoma (NHL) in patients initially diagnosed as Primary Central Nervous System Lymphoma (PCNSL): How much staging is enough?
Journal of Neuro-Oncology
Volume 25, Issue 1 , pp 67-71
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- CNS lymphoma
- systemic non-Hodgkin's lymphoma
- Industry Sectors
- Author Affiliations
- 1. Division of Neuro-Oncology, Department of Neurology, Mayo Clinic and Foundation, 55905, Rochester, MN, USA
- 2. Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 55905, Rochester, MN, USA
- 3. Division of Hematology, and Mayo Comprehensive Cancer Center, Mayo Clinic and Foundation, 55905, Rochester, MN, USA